CRP and non-small cell lung carcinoma: We validated the prognostic value of early on-treatment CRP kinetics in the pivotal phase III OAK trial (n = 758), which compared atezolizumab (anti-PD-L1 antibody) with docetaxel in patients with NSCLC after failure of platinum-containing chemotherapy (Figure 1).